Back to search

Article

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

2023-08-08

Abstract excerpt

A precision medicine approach in type 2 diabetes (T2D) could enhance targeting specific glucose-lowering therapies to individual patients most likely to benefit. We utilised Bayesian non-parametric modelling to develop and validate an individualised treatment selection algorithm for two major T2D drug classes, SGLT2-inhibitors (SGLT2i) and GLP1-receptor agonists (GLP1-RA). The algorithm is designed to predict diff...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2ccfdb05-6492-580c-b739-d99ab1038c2b
DOI
10.1101/2023.08.04.23293636
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesDOI 10.1101/2023.08.04.23293636
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.Semantic proximity
Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical dataSemantic proximity
Identifying type 1 and 2 diabetes in population level data: assessing the accuracy of published approachesSemantic proximity
The iDiabetes Platform: Enhanced Phenotyping of Patients with Diabetes for Precision Diagnosis, Prognosis and Treatment - study protocol for a cluster-randomised controlled study in Tayside, ScotlandSemantic proximity
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 DiabetesSemantic proximity
iDiabetes platform-enhanced phenotyping of patients with diabetes for precision diagnosis, prognosis and treatment: study protocol for a cluster-randomised controlled study in Tayside, Scotland.Semantic proximity
Personalized therapy algorithms for type 2 diabetes: a phenotype-based approachSemantic proximity
Safety and effectiveness of SGLT2-inhibitors in people with type 2 diabetes over 70: UK population-based study using an Instrumental Variable approachSemantic proximity
Heterogeneity of Treatment Effects of Glucose-lowering Drug Classes for Type 2 Diabetes: LEGEND-T2DM Network Real-World EvidenceSemantic proximity
A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetes.Semantic proximity
Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity
Association of SGLT-2 Inhibitors with Thyroid Dysfunction: A Drug-Target Mendelian Randomization StudySemantic proximity
Select a neighboring publication to make it the new centre.